Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes

Engineered SOSIP trimers mimic envelope-glycoprotein spikes, which stud the surface of HIV-1 particles and mediate viral entry into cells. When used for immunizing test animals, they elicit antibodies that neutralize resistant sequence-matched HIV-1 isolates. These neutralizing antibodies recognize epitopes in holes in the glycan shield that covers the trimer. Here, we added glycans to block the most immunogenic neutralization epitopes on BG505 and B41 SOSIP trimers. In addition, we removed selected other glycans to open new holes that might expose new immunogenic epitopes. We immunized rabbits with the various glycan-modified trimers and then dissected the specificities of the antibody responses. Thus, in principle, the antibody response might be diverted from one site to a more cross-reactive one, which would help in the induction of broadly neutralizing antibodies by HIV-1 vaccines based on envelope glycoproteins. ABSTRACT In HIV-1 vaccine research, native-like, soluble envelope glycoprotein SOSIP trimers are widely used for immunizing animals. The epitopes of autologous neutralizing antibodies (NAbs) induced by the BG505 and B41 SOSIP trimers in rabbits and macaques have been mapped to a few holes in the glycan shields that cover most of the protein surfaces. For BG505 trimers, the dominant autologous NAb epitope in rabbits involves residues that line a cavity caused by the absence of a glycan at residue 241. Here, we blocked this epitope in BG505 SOSIPv4.1 trimer immunogens by knocking in an N-linked glycan at residue 241. We then opened holes elsewhere on the trimer by knocking out single N-linked glycans at residues 197, 234, 276, 332, and 355 and found that NAb responses induced by the 241-glycan-bearing BG505 trimers were frequently redirected to the newly opened sites. The strongest evidence for redirection of the NAb response to neoepitopes, through the opening and closing of glycan holes, was obtained from trimer immunogen groups with the highest occupancy of the N241 site. We also attempted to knock in the N289-glycan to block the sole autologous NAb epitope on the B41 SOSIP.v4.1 trimer. Although a retrospective analysis showed that the new N289-glycan site was substantially underoccupied, we found some evidence for redirection of the NAb response to a neoepitope when this site was knocked in and the N356-glycan site knocked out. In neither study, however, was redirection associated with increased neutralization of heterologous tier 2 viruses. IMPORTANCE Engineered SOSIP trimers mimic envelope-glycoprotein spikes, which stud the surface of HIV-1 particles and mediate viral entry into cells. When used for immunizing test animals, they elicit antibodies that neutralize resistant sequence-matched HIV-1 isolates. These neutralizing antibodies recognize epitopes in holes in the glycan shield that covers the trimer. Here, we added glycans to block the most immunogenic neutralization epitopes on BG505 and B41 SOSIP trimers. In addition, we removed selected other glycans to open new holes that might expose new immunogenic epitopes. We immunized rabbits with the various glycan-modified trimers and then dissected the specificities of the antibody responses. Thus, in principle, the antibody response might be diverted from one site to a more cross-reactive one, which would help in the induction of broadly neutralizing antibodies by HIV-1 vaccines based on envelope glycoproteins.

[1]  John P. Moore,et al.  Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C , 2016, PLoS pathogens.

[2]  P. Kwong,et al.  How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design , 2017, Current opinion in HIV and AIDS.

[3]  John P. Moore,et al.  Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers , 2017, Journal of Virology.

[4]  U. Baxa,et al.  Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains. , 2017, Cell reports.

[5]  Cinque S. Soto,et al.  Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. , 2017, Cell reports.

[6]  Tongqing Zhou,et al.  Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. , 2016, Immunity.

[7]  John P. Moore,et al.  Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer , 2016, Journal of Virology.

[8]  J. Mascola,et al.  Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 , 2018, Nature Medicine.

[9]  John P. Moore,et al.  Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits , 2014, Retrovirology.

[10]  G. Debnath,et al.  D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers , 2016 .

[11]  Ian A Wilson,et al.  The HIV‐1 envelope glycoprotein structure: nailing down a moving target , 2017, Immunological reviews.

[12]  John P. Moore,et al.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9 , 2013, Proceedings of the National Academy of Sciences.

[13]  J. Mascola,et al.  HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. , 2018, Immunity.

[14]  Udo Albus,et al.  Book Review: Guide for the Care and use of Laboratory Animals , 1998 .

[15]  John P. Moore,et al.  A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.

[16]  Jennifer S. Wood,et al.  Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. , 2016, Cell reports.

[17]  Raphael Gottardo,et al.  Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2013, Journal of Virology.

[18]  J. Moore,et al.  Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1 , 1996, Journal of virology.

[19]  John P. Moore,et al.  Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.

[20]  John P. Moore,et al.  Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens , 2015, Proceedings of the National Academy of Sciences.

[21]  John P. Moore,et al.  Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity , 2015, Journal of Virology.

[22]  John P. Moore,et al.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? , 2012, AIDS research and human retroviruses.

[23]  S. Munir Alam,et al.  Antibody‐virus co‐evolution in HIV infection: paths for HIV vaccine development , 2017, Immunological reviews.

[24]  L. Stamatatos,et al.  Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo , 2017, The Journal of experimental medicine.

[25]  Q. Sattentau,et al.  The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice , 2015, Clinical and Vaccine Immunology.

[26]  M. Nussenzweig,et al.  Progress toward active or passive HIV-1 vaccination , 2017, The Journal of experimental medicine.

[27]  D. Kabat,et al.  Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry , 2012, Proceedings of the National Academy of Sciences.

[28]  I. Wilson,et al.  Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design , 2018, Cell reports.

[29]  P. Klasse Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. , 2007, Virology.

[30]  Ian A Wilson,et al.  Structure and Immune Recognition of the HIV Glycan Shield. , 2018, Annual review of biophysics.

[31]  David J. Harvey,et al.  Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen , 2018, Cell reports.

[32]  A. Ward,et al.  Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer , 2016, Science.

[33]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[34]  Lloyd H. Michael,et al.  The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.

[35]  John P. Moore,et al.  Native‐like Env trimers as a platform for HIV‐1 vaccine design , 2017, Immunological reviews.

[36]  John P. Moore,et al.  Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes , 2015, Cell.

[37]  A. Trkola,et al.  MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1 , 2011, The Journal of experimental medicine.

[38]  J. Mascola,et al.  Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus , 2017, PloS one.

[39]  Holly Janes,et al.  Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.

[40]  D. Burton,et al.  A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure , 2017, Immunity.

[41]  Ryan McBride,et al.  Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans , 2013, PLoS pathogens.

[42]  K. Kirti,et al.  Colorful World of Microbes: Carotenoids and Their Applications , 2014 .

[43]  L. Stamatatos,et al.  Germline‐targeting immunogens , 2017, Immunological reviews.

[44]  J. Mascola,et al.  Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody , 2015, Journal of Virology.

[45]  Daniel W. Kulp,et al.  Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site , 2015, PLoS pathogens.

[46]  Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Line–adapted HIV-1 Neutralization , 1997, The Journal of experimental medicine.

[47]  John P. Moore,et al.  Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination , 2018, Journal of Virology.

[48]  D. Montefiori,et al.  Neutralization tiers of HIV-1 , 2017, Current opinion in HIV and AIDS.

[49]  Daniel W. Kulp,et al.  Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches , 2017, Immunity.

[50]  Weston B Struwe,et al.  Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein , 2016, Cell reports.

[51]  Florian Klein,et al.  Antibodies in HIV-1 Vaccine Development and Therapy , 2013, Science.

[52]  Tongqing Zhou,et al.  Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity , 2017, Journal of Virology.

[53]  Tongqing Zhou,et al.  Structure and immune recognition of trimeric prefusion HIV-1 Env , 2014, Nature.

[54]  B. Pulendran,et al.  Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques , 2018, PLoS pathogens.

[55]  J. Berzofsky Intrinsic and extrinsic factors in protein antigenic structure. , 1985, Science.

[56]  John P. Moore,et al.  Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. , 2018, Journal of proteome research.

[57]  P. Klasse,et al.  Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. , 2014, Advances in biology.

[58]  G. Air,et al.  Epitopes on protein antigens: Misconceptions and realities , 1990, Cell.

[59]  Bette Korber,et al.  Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth , 2018, Cell reports.

[60]  John R Yates,et al.  Global site-specific N-glycosylation analysis of HIV envelope glycoprotein , 2017, Nature Communications.

[61]  R. Sanders,et al.  Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development? , 2014, Expert review of vaccines.

[62]  William R. Schief,et al.  Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies , 2015, Nature Communications.

[63]  John P. Moore,et al.  A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene , 2015, Journal of Virology.

[64]  Gwo-Yu Chuang,et al.  Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface , 2014, Nature.

[65]  Daniel W. Kulp,et al.  Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding , 2017, Nature Communications.

[66]  John P. Moore,et al.  Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.

[67]  Q. Sattentau,et al.  Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity , 1998, Journal of Virology.

[68]  E. Go,et al.  Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization , 2017, Cell reports.

[69]  R. Wyatt,et al.  Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response , 2017, PLoS pathogens.

[70]  P. Klasse The molecular basis of HIV entry , 2012, Cellular microbiology.